
Immunic rose 7.7% from $6.86 to $7.39, ahead of the S&P 500's +4.7%. Its worst day was Mar 13 (−14.6%), and its low came Dec 30 at $5.10.
Nov 21, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Immunic closed at its lowest level of the year, 25.7% below where the year started.
−2.1% · S&P 500 −0.1%
Immunic shares rose 17.2%, while the S&P 500 fell 1.5%.
+17.2%, the year's best day · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $-0.70 beat the $-1.10 estimate on $0.00 revenue.
+4.1% · S&P 500 −0.6%
Immunic shares fell 14.6%, while the S&P 500 fell 0.6%.
−14.6%, the year's worst day · S&P 500 −0.6%
Immunic shares fell 13.5%, while the S&P 500 fell 1.7%.
−13.5% · S&P 500 −1.7%
Immunic shares rose 13.4%, while the S&P 500 rose 0.2%.
+13.4% · S&P 500 +0.2%
EPS of $-1.08 missed the $-0.91 estimate on $0.00 revenue.
+8.8% · S&P 500 +0.6%
EPS of $-0.80 beat the $-1.18 estimate on $0.00 revenue.
+9.8% · S&P 500 −0.3%
Immunic shares fell 13.6%, while the S&P 500 fell 0.7%.
−13.6% · S&P 500 −0.7%
EPS of $-0.99 missed the $-0.92 estimate on $0.00 revenue.
−3.5% · S&P 500 −0.4%
Where it ended: a close of $7.39 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.75).
Nothing in the past 12 months.
All IMUX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IMUX and SPY from Benzinga historical bars. Not investment advice.